WEBCAST Treatment Innovation in Hodgkin Lymphoma
Integrating New Therapeutic Options with Autologous Transplant Across Clinical Settings
In this activity, experts in the management of Hodgkin lymphoma (HL) discuss progress in integrating novel therapies into treatment protocols that include autologous stem cell transplantation (ASCT) as part of an overall management approach to HL; the experts discuss new evidence on antibody–drug conjugates and immunotherapies as both pre- and post-transplant regimens, as well as practical issues related to the safe and effective use of newer agents in transplant-eligible populations, including the combination of antibody and immune treatments in the HL setting.
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of Hodgkin lymphoma.
Upon completion of this activity, participants should be better able to:
- Summarize transplant eligibility criteria and evidence on the role of novel therapeutics in conjunction with ASCT in the HL setting
- Cite updated evidence on the use of novel therapy for HL as induction therapy, post-transplant consolidation, or as post-ASCT options in relapsed disease
- Integrate novel therapeutics into pre- and post-transplant regimens for patients with HL who are eligible for ASCT
Planning Director: Mary Horowitz
No one in control of content has any relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by independent medical educational grants from Astellas, Merck & Co., Inc., and Shire. This session is open to all registrants of the 2018 BMT Tandem Meetings.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.